Stock listing
Xetra:BH3 PTC Therapeutics, Inc. Aktie
German listing (Xetra) of PTC Therapeutics, Inc. · home listing NASDAQ:PTCT
Follow PTC Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:PTCT
$56.42 USD -3.81 (-6.3%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:PTCT
- Day range
- $56.18 – $58.96 USDNov 20, 2026
- Volume
- 952,599 sharesNov 20, 2026
- Market cap
- $4.71B USDAt the close on Nov 20, 2026 · price × 83.54M shares outstanding
- 52-week range
- $56.18 – $90.87 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $69.05M USDMedian day 965,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PTCT · Home | $56.42 USD | -3.81 (-6.3%) | 952,599 | $58.80 | $58.96 | $56.18 | $60.23 | Close on Nov 20, 2026 |
| Dusseldorf:BH3 | €51.76 EUR | -1.76 (-3.3%) | — | €51.94 | €52.32 | €51.76 | €53.52 | Close on Nov 20, 2026 |
| Frankfurt:BH3 | €51.62 EUR | -1.60 (-3.0%) | — | €51.58 | €51.62 | €51.58 | €53.22 | Close on Nov 20, 2026 |
| Munich:BH3 | €53.08 EUR | -2.96 (-5.3%) | — | €53.08 | €53.08 | €53.08 | €56.04 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PTCT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $56.42 | -3.81 | -6.3% | $58.80 | $58.96 | $56.18 | 952,599 | |
| $60.23 | -0.13 | -0.2% | $59.99 | $60.80 | $59.86 | 640,646 | |
| $60.36 | -0.61 | -1.0% | $60.63 | $60.97 | $58.88 | 1,077,752 | |
| $60.97 | -2.52 | -4.0% | $63.26 | $63.95 | $60.62 | 738,542 | |
| $63.49 | +0.13 | +0.2% | $63.12 | $63.74 | $62.51 | 502,867 | |
| $63.36 | -1.55 | -2.4% | $64.56 | $64.86 | $63.27 | 538,717 | |
| $64.91 | +0.77 | +1.2% | $64.03 | $65.04 | $63.84 | 719,597 | |
| $64.14 | -0.89 | -1.4% | $64.46 | $65.15 | $63.52 | 630,008 | |
| $65.03 | -0.41 | -0.6% | $66.91 | $66.91 | $64.13 | 843,279 | |
| $65.44 | -0.23 | -0.4% | $65.99 | $66.67 | $65.18 | 889,219 | |
| $65.67 | -3.30 | -4.8% | $68.80 | $69.59 | $65.45 | 1,228,468 | |
| $68.97 | +0.85 | +1.2% | $69.68 | $70.11 | $66.87 | 1,266,047 | |
| $68.12 | +7.24 | +11.9% | $64.14 | $68.72 | $63.16 | 2,643,738 | |
| $60.88 | +0.91 | +1.5% | $61.05 | $62.16 | $59.16 | 1,334,171 | |
| $59.97 | -4.49 | -7.0% | $64.75 | $65.34 | $59.65 | 2,349,386 | |
| $64.46 | +1.44 | +2.3% | $63.51 | $65.00 | $63.51 | 1,523,222 | |
| $63.02 | +0.93 | +1.5% | $61.47 | $63.11 | $61.00 | 902,770 | |
| $62.09 | +1.02 | +1.7% | $61.07 | $62.28 | $59.87 | 1,114,121 | |
| $61.07 | +0.48 | +0.8% | $60.84 | $61.85 | $60.46 | 708,009 | |
| $60.59 | -2.45 | -3.9% | $62.30 | $63.49 | $59.97 | 674,200 | |
| $63.04 | +0.42 | +0.7% | $62.62 | $63.49 | $62.24 | 675,400 | |
| $62.62 | -0.30 | -0.5% | $63.14 | $63.74 | $62.41 | 944,200 | |
| $62.92 | +1.39 | +2.3% | $62.27 | $63.24 | $61.58 | 965,800 | |
| $61.53 | +2.29 | +3.9% | $60.13 | $61.74 | $59.35 | 944,000 | |
| $59.24 | -1.75 | -2.9% | $61.08 | $61.73 | $58.98 | 789,000 | |
| $60.99 | +1.32 | +2.2% | $61.08 | $62.31 | $59.88 | 1,051,900 | |
| $59.67 | -0.25 | -0.4% | $59.30 | $60.69 | $58.80 | 1,519,800 | |
| $59.92 | -3.00 | -4.8% | $62.64 | $62.75 | $59.82 | 1,051,400 | |
| $62.92 | -1.78 | -2.8% | $64.80 | $65.03 | $62.88 | 745,200 | |
| $64.70 | +2.14 | +3.4% | $62.52 | $64.73 | $62.20 | 1,171,200 | |
| $62.56 | -0.67 | -1.1% | $62.66 | $62.86 | $61.65 | 1,227,500 | |
| $63.23 | -0.47 | -0.7% | $63.19 | $64.04 | $62.84 | 1,040,500 | |
| $63.70 | +0.05 | +0.1% | $64.53 | $65.27 | $62.92 | 1,265,000 | |
| $63.65 | +0.19 | +0.3% | $63.42 | $64.47 | $62.60 | 1,044,000 | |
| $63.46 | -0.67 | -1.0% | $64.81 | $65.40 | $62.80 | 895,600 | |
| $64.13 | -0.65 | -1.0% | $64.70 | $65.57 | $63.40 | 1,197,800 | |
| $64.78 | -0.18 | -0.3% | $65.16 | $65.50 | $64.15 | 1,043,300 | |
| $64.96 | -0.99 | -1.5% | $65.51 | $65.97 | $64.27 | 900,400 | |
| $65.95 | +3.28 | +5.2% | $62.35 | $66.26 | $62.30 | 1,913,800 | |
| $62.67 | +0.39 | +0.6% | $62.65 | $63.44 | $61.66 | 1,203,000 | |
| $62.28 | -0.06 | -0.1% | $62.23 | $62.76 | $61.23 | 1,754,200 | |
| $62.34 | -3.62 | -5.5% | $65.80 | $66.15 | $62.24 | 1,101,100 | |
| $65.96 | +0.70 | +1.1% | $66.24 | $66.58 | $65.36 | 1,307,200 | |
| $65.26 | -0.11 | -0.2% | $65.93 | $66.21 | $64.99 | 1,086,200 | |
| $65.37 | -2.63 | -3.9% | $68.00 | $68.01 | $65.18 | 3,865,000 | |
| $68.00 | +0.41 | +0.6% | $68.84 | $68.84 | $67.22 | 1,115,300 | |
| $67.59 | +1.94 | +3.0% | $65.99 | $67.90 | $65.80 | 1,397,900 | |
| $65.65 | -0.83 | -1.2% | $66.51 | $66.54 | $65.06 | 1,034,200 | |
| $66.48 | +0.42 | +0.6% | $67.09 | $67.99 | $65.91 | 1,018,800 | |
| $66.06 | -1.31 | -1.9% | $67.80 | $68.48 | $65.91 | 792,900 | |
| $67.37 | -0.20 | -0.3% | $66.84 | $67.78 | $66.47 | 1,007,000 | |
| $67.57 | -1.24 | -1.8% | $68.08 | $68.84 | $67.50 | 1,066,500 | |
| $68.81 | -0.49 | -0.7% | $67.81 | $70.08 | $67.48 | 1,118,300 | |
| $69.30 | -2.10 | -2.9% | $70.62 | $71.41 | $69.26 | 673,500 | |
| $71.40 | -0.39 | -0.5% | $71.76 | $71.97 | $70.55 | 654,500 | |
| $71.79 | +1.23 | +1.7% | $71.15 | $72.68 | $69.84 | 902,600 | |
| $70.56 | +1.02 | +1.5% | $69.42 | $70.84 | $69.05 | 691,000 | |
| $69.54 | -0.55 | -0.8% | $69.98 | $70.42 | $68.76 | 841,100 | |
| $70.09 | -1.72 | -2.4% | $71.08 | $71.49 | $69.61 | 692,700 | |
| $71.81 | -0.88 | -1.2% | $72.11 | $72.66 | $70.91 | 746,300 | |
| $72.69 | -0.78 | -1.1% | $73.18 | $73.53 | $71.81 | 533,600 | |
| $73.47 | +2.41 | +3.4% | $71.69 | $73.47 | $71.69 | 624,463 | |
| $71.06 | +1.24 | +1.8% | $69.67 | $71.45 | $68.02 | 897,681 | |
| $69.82 | -0.70 | -1.0% | $70.54 | $71.36 | $69.79 | 674,700 | |
| $70.52 | -3.15 | -4.3% | $73.05 | $73.56 | $70.46 | 802,500 |
- Ticker
- Xetra:BH3
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Xetra
- Currency
- EUR
What changed lately
Latest news release · Nov 3, 2026
PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program
Latest earnings call · Oct 29, 2026
PTC Therapeutics (NASDAQ:PTCT) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Oct 29, 2026
Corporate Update (October 2026)
Corporate update · 31 slides
Latest news
PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program
Nov 3, 2026
Closed $68.12 (+11.9%) on Nov 3, 2026
PTC Therapeutics to Participate in Upcoming Investor Conferences
Nov 2, 2026
Closed $60.88 (+1.5%) on Nov 2, 2026
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 30, 2026
Closed $60.88 (+1.5%) on Nov 2, 2026
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Oct 29, 2026
Closed $59.97 (-7.0%) on Oct 30, 2026
PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026
Oct 15, 2026
Closed $60.99 (+2.2%) on Oct 15, 2026
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
Sep 21, 2026
Closed $65.96 (+1.1%) on Sep 22, 2026
PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile
Aug 24, 2026
Closed $71.06 (+1.8%) on Aug 24, 2026
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
Aug 12, 2026
Closed $71.97 (-0.9%) on Aug 13, 2026
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Jul 30, 2026
Closed $68.01 (-9.9%) on Jul 31, 2026
PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026
Jul 16, 2026
Closed $78.52 (-0.4%) on Jul 16, 2026
PTC Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 25 in the last 12 months · 217 in all · newest Nov 3, 2026 · oldest 2019
- Calls
- 22 calls with a replay · 22 with a transcript · latest Oct 29, 2026
- Decks
- 33 decks · latest Oct 29, 2026
Where PTC Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PTCT · Home listing | NASDAQ | United States | USD |
| gettex:BH3 | gettex | Germany | EUR |
| LS Exchange:A1W0MW | LS Exchange | Germany | EUR |
| Lang & Schwarz:A1W0MW | Lang & Schwarz | Germany | EUR |
| BOATS:PTCT | BOATS | United States | USD |
| BX Swiss:P91 | BX Swiss | Switzerland | CHF |
| Dusseldorf:BH3 | Dusseldorf | Germany | EUR |
| Frankfurt:BH3 | Frankfurt | Germany | EUR |
| Hamburg:BH3 | Hamburg | Germany | EUR |
| Munich:BH3 | Munich | Germany | EUR |
| Stuttgart:BH3 | Stuttgart | Germany | EUR |
| Tradegate:BH3 | Tradegate | Germany | EUR |
| Hanover:BH3 | Hanover | Germany | EUR |
| Xetra:BH3 · This page | Xetra | Germany | EUR |
Valuation
EV/sales 2.7× against a median of 7.0×: the lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $3.12B USD
- P/E
- Loss
- EV/sales
- 2.7×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- Not reported
- Operating margin
- 12.8%
- Net margin
- −9.2%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 0.88
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| PTC Therapeutics, Inc. · NASDAQ:PTCT | US$4.71B | US$3.12B | n/a | 2.7× | n/a | n/a | −9.2% | n/a | 0.88 |
| SK Biopharmaceuticals Co., Ltd. · KRX:326030 | US$5.05B | US$4.77B | 16.9× | 7.5× | 20.1× | 6.7× | 46.6% | 0.0× | n/a |
| Veradermics, Incorporated · NYSE:MANE | US$5.04B | US$4.25B | n/a | n/a | n/a | 6.3× | n/a | 0.0× | 1.13 |
| Liquidia Corporation · NASDAQ:LQDA | US$4.90B | US$4.68B | n/a | 7.5× | n/a | n/a | −15.2% | n/a | 0.84 |
| Erasca, Inc. · NASDAQ:ERAS | US$4.78B | US$4.18B | n/a | n/a | n/a | 5.2× | n/a | 0.1× | 1.51 |
| Dianthus Therapeutics, Inc. · NASDAQ:DNTH | US$4.76B | US$3.92B | n/a | 1,444× | n/a | 3.8× | n/a | 0.0× | 0.90 |
| Cogent Biosciences, Inc. · NASDAQ:COGT | US$4.65B | US$4.08B | n/a | n/a | n/a | 9.0× | n/a | 0.4× | 1.30 |
| Kiniksa Pharmaceuticals International, plc · NASDAQ:KNSA | US$4.53B | US$3.97B | 41.4× | 4.2× | 29.9× | 6.4× | 11.6% | 0.0× | 0.57 |
| Travere Therapeutics, Inc. · NASDAQ:TVTX | US$4.51B | US$4.21B | n/a | 6.5× | n/a | 200× | −18.7% | 0.0× | 1.31 |
| Ionis Pharmaceuticals, Inc. · NASDAQ:IONS | US$4.43B | US$4.70B | n/a | 4.9× | n/a | 11.3× | −56.9% | 5.5× | 0.40 |
| Edgewise Therapeutics, Inc. · NASDAQ:EWTX | US$4.37B | US$2.63B | 4.3× | n/a | n/a | 2.7× | n/a | 0.0× | 1.12 |
| Median of the others | US$4.70B | US$4.19B | 16.9× | 7.0× | 25.0× | 6.4× | −15.2% | 0.0× | 1.12 |
Forecasts
9 strong buy · 4 buy · 2 hold · Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.
- Price target
- 100.47 USD · Analysts' mean
- EPS, year to Dec 2026
- 0.94 · 2 analysts
- Revenue, year to Dec 2026
- 1.32B · 14 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Matthew B. Klein | Chief Executive Officer |
| Pierre Gravier | Chief Financial Officer |
| Mark E. Boulding | Executive Vice President and Chief Legal Officer |
| Christine Utter | Senior Vice President, Chief Accounting Officer and Head of People Services |
| Linda Montella-Carter | Senior Vice President and Chief Information Officer |
| Mary Frances Harmon | Senior Vice President, Corporate and Patient Relations |
| Patrice Thornton | Senior Vice President, Human Resources |
| Eric Pauwels | Chief Business Officer |
| John Baird | Chief of Staff to the CEO |
| Lee Golden | Chief Medical Officer |
| Neil Almstead | Chief Technical Operations Officer |
Board
| Director | Role |
|---|---|
| Glenn D. Steele | Chairman, GSteele Health Solutions |
| Michael Schmertzler | Chairman |
| Jessica Chutter | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| PTC Therapeutics (NASDAQ:PTCT) Q3 2026 Earnings Call | Thu, Oct 29, 2026 · 4:30 PM ET | Replay |
| PTC Therapeutics (NASDAQ:PTCT) Q2 2026 Earnings Call | Thu, Jul 30, 2026 · 4:30 PM ET | Replay |
| PTC Therapeutics (NASDAQ:PTCT) Q1 2026 Earnings Call | Thu, May 07, 2026 · 4:30 PM ET | Replay |
| PTC Therapeutics (NASDAQ:PTCT) Q4 2025 Earnings Call | Thu, Feb 19, 2026 · 4:30 PM ET | Replay |
| PTC Therapeutics (NASDAQ:PTCT) Q3 2025 Earnings Call | Tue, Nov 04, 2025 · 4:30 PM ET | Replay |
| PTC Therapeutics (NASDAQ:PTCT) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 4:30 PM ET | Replay |
| PTC Therapeutics (NASDAQ:PTCT) Q1 2025 Earnings Call | Tue, May 06, 2025 · 4:30 PM ET | Replay |
| PTC Therapeutics (NASDAQ:PTCT) Q4 2024 Earnings Call | Thu, Feb 27, 2025 · 4:30 PM ET | Replay |
| PTC Therapeutics (NASDAQ:PTCT) Q3 2024 Earnings Call | Thu, Nov 07, 2024 · 4:30 PM ET | Replay |
| PTC Therapeutics (NASDAQ:PTCT) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 4:30 PM ET | Replay |
All 22 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 29, 2026 · After close | −7.0% |
| Q2 2026 | Jul 30, 2026 · After close | −9.9% |
| Q1 2026 | May 7, 2026 · After close | +14.3% |
| Q4 2025 | Feb 19, 2026 · After close | +1.1% |
| Q3 2025 | Nov 4, 2025 · After close | +6.0% |
| Q2 2025 | Aug 7, 2025 · After close | −9.9% |
| Q1 2025 | May 6, 2025 · After close | +12.6% |
| Q4 2024 | Feb 26, 2025 · After close | −0.8% |
| Q3 2024 | Nov 7, 2024 · After close | +3.1% |
| Q2 2024 | Aug 8, 2024 · After close | −3.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 25, 2024 · After close | +12.1% |
| Q4 2023 | Feb 29, 2024 · After close | +13.3% |
| Q3 2023 | Oct 26, 2023 · After close | −22.7% |
| Q2 2023 | Aug 3, 2023 · After close | −4.0% |
| Q1 2023 | Apr 27, 2023 · After close | +4.8% |
| Q4 2022 | Feb 21, 2023 · After close | −1.1% |
| Q3 2022 | Oct 27, 2022 · After close | −13.7% |
| Q2 2022 | Aug 4, 2022 · After close | +8.7% |
| Q1 2022 | May 3, 2022 · After close | +2.7% |
| Q4 2021 | Feb 22, 2022 · After close | −7.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (October 2026) | Corporate update | 31 slides | Oct 29, 2026 |
| Investor Presentation (July 2026) | Investor deck | 28 slides | July 2026 |
| Technical Presentation (April 2026) | Technical | 18 slides | Apr 28, 2026 |
| J.P. Morgan 2026 Healthcare Conference | Conference | 25 slides | Jan 12, 2026 |
| Investor Day (December 2025) | Investor day | 113 slides | Dec 2, 2025 |
| Technical Presentation (May 2025) | Technical | 22 slides | May 5, 2025 |
| J.P. Morgan Healthcare Conference 2025 | Conference | 31 slides | Jan 13, 2025 |
| Technical Presentation (June 2024) | Technical | 25 slides | Jun 20, 2024 |
| J.P. Morgan Healthcare Conference 2024 | Conference | 30 slides | Jan 8, 2024 |
| Investor Day (July 2023) | Investor day | 58 slides | Jul 19, 2023 |
All 33 decks
Financings
| Raise | Date |
|---|---|
| 0% Convertible Senior Notes due 2031 Update: US$500M Use of proceeds: About $328.8 million to repurchase 2026 convertible notes; rest for general corporate purposes, including further repurchases or repayment of 2026 notes | Jun 16, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.73B | 806.8M | 937.8M | 698.8M | 538.6M | 380.8M | 307.0M | 264.7M | 194.4M | 82.7M |
| Cost of revenue | 12.1M | 12.7M | 4.58M | 0 | ||||||
| Gross profit | 294.8M | 252.1M | 189.8M | 82.7M | ||||||
| Research and development | 455.2M | 534.5M | 666.6M | 651.5M | 540.7M | 477.6M | 257.5M | 172.0M | 117.5M | 117.6M |
| Selling, general and administrative | 347.1M | 300.9M | 332.5M | 326.0M | 285.8M | 245.2M | 202.5M | 153.5M | 121.3M | 97.1M |
| Operating income | 866.9M | -302.6M | -439.5M | -447.4M | -374.4M | -431.8M | -241.2M | -115.7M | -64.3M | -132.1M |
| Depreciation and amortization | 38.8M | 75.7M | 236.6M | 128.8M | 64.1M | 43.5M | 32.2M | 26.1M | 17.7M | 3.29M |
| EBITDA | 905.8M | -226.9M | -202.9M | -318.6M | -310.3M | -388.3M | -209.0M | -89.6M | -46.6M | -128.8M |
| Income before tax | 696.6M | -363.1M | -696.1M | -587.5M | -518.3M | -402.9M | -239.9M | -128.1M | -77.7M | -141.5M |
| Income tax | 14.0M | 176.0K | -69.5M | -28.5M | 5.56M | 35.2M | 11.7M | -29.0K | 1.33M | 569.0K |
| Net income | 682.6M | -363.3M | -626.6M | -559.0M | -523.9M | -438.2M | -251.6M | -128.1M | -79.0M | -142.1M |
| Earnings per share, basic | 8.58 | -4.73 | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | -4.17 |
| Earnings per share, diluted | 7.78 | -4.73 | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | -4.17 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 984.6M | 779.7M | 594.0M | 279.8M | 189.7M | 208.8M | 288.0M | 169.5M | 111.8M | 58.3M |
| Short-term investments | 960.7M | 360.0M | 282.7M | 130.9M | 583.7M | 894.8M | 398.5M | 58.1M | 79.5M | 173.3M |
| Receivables | 181.6M | 158.6M | 160.8M | 155.6M | 110.5M | 69.9M | 55.5M | 67.9M | 40.4M | 24.9M |
| Inventory | 79.6M | 23.2M | 30.6M | 21.8M | 15.9M | 18.7M | 19.3M | 16.1M | 10.8M | 0 |
| Current assets | 2.27B | 1.37B | 1.22B | 693.8M | 954.4M | 1.23B | 779.3M | 320.9M | 249.1M | 261.3M |
| Property, plant and equipment | 55.4M | 61.0M | 87.1M | 72.6M | 52.6M | 33.8M | 21.5M | 12.7M | 8.38M | 7.43M |
| Goodwill | 82.3M | 82.3M | 82.3M | 82.3M | 82.3M | 82.3M | 82.3M | 82.3M | 0 | |
| Total assets | 2.90B | 1.71B | 1.90B | 1.71B | 1.94B | 2.21B | 1.62B | 1.12B | 391.7M | 269.3M |
| Accounts payable | 45.5M | 17.3M | 6.04M | 27.3M | 23.0M | 18.7M | 10.3M | 6.00M | 15.3M | 6.30M |
| Current liabilities | 968.4M | 581.0M | 603.1M | 406.2M | 509.3M | 277.3M | 235.9M | 166.8M | 82.0M | 49.6M |
| Long-term debt | 285.4M | 284.2M | 571.7M | 281.9M | 309.1M | 293.9M | 141.3M | 145.0M | 98.2M | |
| Total debt | 286.6M | 285.4M | 284.2M | 571.7M | 431.4M | 309.1M | 313.9M | 153.0M | 145.0M | 98.2M |
| Total liabilities | 3.10B | 2.80B | 2.71B | 2.05B | 1.94B | 1.73B | 1.03B | 768.5M | 235.2M | 149.8M |
| Shareholders' equity | -205.3M | -1.10B | -818.6M | -347.1M | 1.44M | 482.0M | 594.3M | 350.7M | 156.4M | 119.6M |
| Shares outstanding | 81.5M | 77.7M | 75.7M | 73.1M | 70.8M | 69.7M | 61.9M | 50.6M | 41.6M | 34.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 711.2M | -107.7M | -158.4M | -356.7M | -251.3M | -194.1M | -98.6M | -27.6M | -10.1M | -103.6M |
| Capital spending | -8.86M | -6.50M | -28.4M | -32.0M | -28.2M | -17.8M | -13.8M | -7.10M | -3.10M | -1.78M |
| Free cash flow | 702.3M | -114.2M | -186.9M | -388.7M | -279.5M | -211.9M | -112.4M | -34.7M | -13.2M | -105.3M |
| Cash from investing | -862.0M | 44.2M | -176.7M | 290.2M | 219.2M | -561.5M | -387.2M | -42.6M | 13.1M | 104.5M |
| Cash from financing | 331.1M | 255.9M | 646.4M | 168.0M | 20.9M | 668.7M | 613.2M | 131.6M | 44.2M | 968.0K |
| Change in cash | 203.0M | 185.0M | 314.4M | 98.7M | -19.1M | -79.2M | 126.0M | 57.7M | 53.5M | 299.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 16, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 3, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Oct 29, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 30, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 21, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 28, 2026 | Material contract | SEC |
| 144/A · Notice of proposed sale, amended | Aug 25, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 13, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 30, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Jul 30, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 14, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 25, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 24, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 22, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 18, 2026 | Material contract | SEC |
| 144 · Notice of proposed sale | Jun 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 17, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 16, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 10, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 9, 2026 | Management or board change | SEC |
| 8-K · Current report | Jun 5, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | May 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 14, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 14, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 8, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 30, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 28, 2026 | Current report | SEC |
| 4 · Change in ownership | Apr 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 21, 2026 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 20, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 20, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 20, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 1, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 25, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 19, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 19, 2026 | Results | SEC |
| 144 · Notice of proposed sale | Feb 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 9, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 144 · Notice of proposed sale | Jan 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 7, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 30, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 29, 2025 | Material contract | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 19, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 4, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from PTC Therapeutics, Inc.’s releases · as of Oct 27, 2026
- Common shares
- 83,544,284
- Fully diluted
- 83,544,284
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 83,544,284 | Oct 27, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 27, 2026 | 83,544,284 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Adam Koppel Other companies: Kailera Therapeutics, Inc. (Partner, Bain Capital Life Sciences · Since at least Apr 16, 2026); Cerevel Therapeutics Holdings Inc (Director · Oct 27, 2020 – Aug 1, 2024 · Past); Foghorn Therapeutics Inc. (Director · Oct 22, 2020 – Dec 29, 2024 · Past); BCLS Acquisition Corp (Director · Oct 21, 2020 – Oct 26, 2020 · Past); Replimune Group, Inc. (Director · Jul 24, 2018 – Jul 24, 2018 · Past); Aptinyx Inc (Director · Jun 20, 2018 – May 26, 2022 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Dicerna Pharmaceuticals Inc (Director · Apr 11, 2017 – Dec 28, 2021 · Past); Trevena, Inc. (Director · Sep 17, 2014 – May 16, 2018 · Past); Biogen Inc. (EVP, Strategy and Bus. Dev. · May 15, 2014 – Jun 6, 2016 · Past) | Director · Jun 19, 2013 – Jan 3, 2017 · Past |
| Ronald C Renaud Jr Other companies: Kailera Therapeutics, Inc. (CEO & President, Director · Since at least Apr 16, 2026); Upstream Bio, Inc. (Director · Since at least Oct 10, 2024); Cerevel Therapeutics Holdings Inc (President & CEO, Director · Jun 12, 2023 – Aug 1, 2024 · Past); ImageneBio, Inc. (Director · Mar 25, 2021 – Jun 9, 2022 · Past); Atara Biotherapeutics, Inc. (Director · Apr 29, 2020 – Jun 23, 2022 · Past); Translate Bio Inc (Chief Executive Officer, Director · Jun 27, 2018 – Sep 14, 2021 · Past); Chimerix Inc (Director · Dec 17, 2014 – Jun 20, 2019 · Past); Akebia Therapeutics, Inc. (Director · Sep 12, 2014 – Jun 14, 2018 · Past); Idenix Pharmaceuticals Inc (President & CEO, Director · Jun 28, 2007 – Aug 5, 2014 · Past); Keryx Biopharmaceuticals Inc (Chief Financial Officer · Feb 14, 2006 – Feb 14, 2007 · Past) | Director · Jun 10, 2014 – Jan 3, 2017 · Past |
| Jerome Zeldis Other companies: NexGel, Inc (Director · Since at least Mar 8, 2021); Soligenix, Inc. (Board Director · Since at least Jun 22, 2011); NexImmune, Inc. (Executive VP of Research & Dev · Feb 11, 2021 – Apr 5, 2022 · Past); MetaStat Inc (Director · Oct 11, 2017 – Oct 11, 2017 · Past); Beyond Air, Inc. (Director · Mar 14, 2017 – Mar 14, 2017 · Past); Sorrento Therapeutics, Inc. (See Remarks · Aug 12, 2016 – Nov 26, 2018 · Past); Streamex Corp. (Director · Jul 20, 2015 – Jul 14, 2020 · Past) | Director · Since at least Jun 19, 2013 |
| David P. Southwell Other companies: Rocket Pharmaceuticals, Inc. (Director · Since at least Feb 17, 2015); TScan Therapeutics, Inc. (Chief Executive Officer, Director · Jul 15, 2021 – Feb 2, 2023 · Past); Spero Therapeutics, Inc. (Director · Feb 1, 2018 – Jun 5, 2018 · Past); Human Genome Sciences Inc (Chief Financial Officer · Jul 23, 2008 – Jul 30, 2012 · Past); Biosphere Medical Inc (Director · May 10, 2006 – Sep 10, 2010 · Past); Sepracor Inc (Chief Financial Officer · Dec 31, 2005 – Sep 10, 2007 · Past) | Director · Since at least Jun 19, 2013 |
| Dawn Svoronos Other companies: Adverum Biotechnologies Inc (Director · Since at least Dec 9, 2020); Xenon Pharmaceuticals Inc. (Director · Since at least Sep 27, 2016); Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past); Global Blood Therapeutics Inc (Director · Dec 19, 2018 – Oct 5, 2022 · Past); Endocyte Inc (Director · May 3, 2018 – Dec 21, 2018 · Past); Medivation Inc (Director · Apr 22, 2013 – Sep 28, 2016 · Past) | Director · Jun 10, 2016 – Jun 9, 2022 · Past |
| Axel Bolte Other companies: Inozyme Pharma Inc (Director · Since at least Jul 23, 2020); Allena Pharmaceuticals Inc (Director · Nov 1, 2017 – Jun 8, 2018 · Past); Nabriva Therapeutics AG (Director · Dec 30, 2016 – Dec 30, 2016 · Past); IVERIC bio Inc (Director · Sep 24, 2013 – Jul 11, 2023 · Past) | Director · Jun 19, 2013 – Jun 25, 2013 · Past |
| Emma Reeve Other companies: Whitehawk Therapeutics, Inc. (Director · Since at least Sep 8, 2021); Editas Medicine, Inc. (Director · Sep 3, 2021 – May 30, 2024 · Past); Constellation Pharmaceuticals Inc (Chief Financial Officer · Jul 18, 2018 – Jul 15, 2021 · Past); PAREXEL International Corp (Corp. VP & Interim CFO · Jul 16, 2016 – Dec 7, 2016 · Past) | Director · Since at least Dec 14, 2018 |
| Richard Aldrich Other companies: KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 3, 2018 · Past); Concert Pharmaceuticals Inc (Director · Feb 12, 2014 – Mar 6, 2023 · Past); Tempest Therapeutics, Inc. (Director · Jun 11, 2012 – Dec 7, 2018 · Past); Verastem, Inc. (Director · Jan 26, 2012 – Jun 10, 2014 · Past) | Director · Mar 7, 2013 – Jun 8, 2015 · Past |
| Alethia Young Other companies: Pacira BioSciences, Inc. (Independent Director · Since at least Oct 6, 2023); Bicycle Therapeutics PLC (Chief Financial Officer · Since at least Jul 17, 2023); LENZ Therapeutics, Inc. (Chief Financial Officer · Apr 1, 2022 – Feb 21, 2023 · Past) | Director · Since at least Jun 8, 2022 |
| Marcio Souza Other companies: Praxis Precision Medicines, Inc. (President & Chief Executive Officer · Since at least Oct 15, 2020); Spyre Therapeutics, Inc. (Director · Jun 18, 2021 – Aug 25, 2022 · Past); ClearPoint Neuro Inc. (Director · May 17, 2019 – May 17, 2019 · Past) | Chief Operating Officer · May 31, 2017 – Feb 10, 2020 · Past |
All 36 people
| Person | Seat |
|---|---|
| Stephanie Okey Other companies: Crinetics Pharmaceuticals, Inc. (Director · Since at least Jul 15, 2019); Catalent Inc (Director · Aug 28, 2023 – Dec 18, 2024 · Past); Albireo Pharma Inc (Director · Jun 8, 2018 – Mar 2, 2023 · Past) | Director · Since at least Dec 14, 2018 |
| Lee Golden Other companies: Cadrenal Therapeutics, Inc. (Board Member · Since at least Nov 24, 2025); MetaVia Inc. (Chief Medical Officer · Oct 5, 2016 – Jan 28, 2018 · Past) | EVP & CHIEF MEDICAL OFFICER · Since at least Jun 6, 2023 |
| Tuyen Ong Other companies: Disc Medicine, Inc. (Director · Feb 5, 2021 – Oct 4, 2021 · Past); Nightstar Therapeutics PLC (Chief Development Officer · Jan 1, 2019 – Jun 7, 2019 · Past) | Chief Medical Officer · Apr 22, 2016 – Jan 3, 2017 · Past |
| Emily Hill Other companies: Replimune Group, Inc. (Chief Financial Officer · Since at least Sep 18, 2023) | CHIEF FINANCIAL OFFICER · May 31, 2019 – Mar 27, 2023 · Past |
| Eric Pauwels Other companies: NPS Pharmaceuticals Inc (President, NPS Pharma Int'l · Oct 17, 2011 – Feb 21, 2015 · Past) | Chief Business Officer · Since at least Apr 16, 2020 |
| Jessica Chutter Other companies: Tectonic Therapeutic, Inc. (Director · Since at least Apr 23, 2026) | Director · Since at least Mar 24, 2026 |
| Matthew B. Klein Other companies: ClearPoint Neuro Inc. (Director · Since at least Apr 16, 2020) | Chief Executive Officer · Since at least Apr 16, 2020 |
| Michael L Kranda Other companies: Anesiva Inc (President and CEO, Director · Jun 16, 2008 – Dec 3, 2008 · Past) | Director · Jun 19, 2013 – Mar 16, 2015 · Past |
| Michael Schmertzler Other companies: Hamilton Lane Incorporated (Independent Director · Since Jul 22, 2026) | Director · Since at least Jan 29, 2013 |
| Pierre Gravier Other companies: Filana Therapeutics, Inc. (Independent Director · Since at least Dec 6, 2023) | Chief Financial Officer · Since at least Jul 13, 2023 |
| Shane William Charles Kovacs Other companies: Olema Pharmaceuticals, Inc. (CH. OPERATING & FINANCIAL OFF. · Since at least Jun 15, 2020) | Chief Financial Officer · Sep 26, 2016 – May 9, 2017 · Past |
| Stuart Walter Peltz Other companies: Orchestra BioMed Holdings, Inc. (Director · Aug 3, 2020 – Aug 3, 2020 · Past) | CHIEF EXECUTIVE OFFICER, Director · Jun 19, 2013 – Jan 31, 2023 · Past |
| Allan Steven Jacobson | Director · Since at least Jun 19, 2013 |
| Christine Utter | Senior Vice President, Chief Accounting Officer and Head of People Services · Since at least Jun 2, 2017 |
| Glenn D. Steele | Chairman, GSteele Health Solutions · Since at least Oct 2, 2026 |
| Glenn Md Phd Steele Jr | Director · Since at least Jan 5, 2023 |
| Hege Elisabeth Sollie-Zetlmayer | Director · Since at least Jul 28, 2026 |
| Jay Allan Barth | VP, Clinical Development · Jun 19, 2013 – Jun 19, 2013 · Past |
| John Baird | Chief of Staff to the CEO · Since at least Nov 5, 2026 |
| Linda Montella-Carter | Senior Vice President and Chief Information Officer · Since at least Nov 5, 2026 |
| Mark E. Boulding | Executive Vice President and Chief Legal Officer · Since at least Jan 3, 2018 |
| Mary Frances Harmon | Senior Vice President, Corporate and Patient Relations · Since at least Nov 5, 2026 |
| Mary L Smith | Director · Since at least Jun 8, 2021 |
| Neil Almstead | Chief Technical Operations Officer · Since at least Jan 3, 2018 |
| Patrice Thornton | Senior Vice President, Human Resources · Since at least Nov 5, 2026 |
| William F Bell Jr | Director · Feb 15, 2024 – Feb 15, 2024 · Past |
Log in to ask 6ix AI your own questions about PTC Therapeutics, Inc.